Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 274,600 shares, a decrease of 16.0% from the January 31st total of 326,800 shares. Approximately 9.2% of the company’s shares are short sold. Based on an average daily volume of 955,100 shares, the short-interest ratio is currently 0.3 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Clearmind Medicine stock. Virtu Financial LLC acquired a new position in shares of Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 39,479 shares of the company’s stock, valued at approximately $54,000. Virtu Financial LLC owned 0.92% of Clearmind Medicine at the end of the most recent reporting period. Institutional investors and hedge funds own 96.05% of the company’s stock.
Clearmind Medicine Price Performance
NASDAQ:CMND opened at $1.11 on Friday. The firm has a market cap of $4.73 million, a price-to-earnings ratio of -0.59 and a beta of 1.04. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average is $1.39 and its two-hundred day moving average is $1.37. Clearmind Medicine has a 12-month low of $0.95 and a 12-month high of $2.30.
About Clearmind Medicine
Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
Read More
- Five stocks we like better than Clearmind Medicine
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- 3 Tickers Leading a Meme Stock Revival
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- How to Profit From Value Investing
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.